S
NAVB

SignatureFD’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

SignatureFD’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-25
Closed – – 2054
2018
Q2 		$0 Buy
+25
New +$131 ﹤0.01% 2017
2016
Q4 		– Sell
-25
Closed – – 1445
2016
Q3 		$0 Buy
+25
New +$316 ﹤0.01% 1670

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SFS
Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SignatureFD's NAVB Position: Q3 2018 in Review

SignatureFD sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2018, closing a stake of 25 shares.

SignatureFD first reported a position in NAVB in Q3 2016 and held it in 2 quarters. The position peaked at $0 in Q2 2018. 53 funds tracked by Wall St. Rank hold NAVB as of Q3 2018.

  • SignatureFD reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
  • SignatureFD sold 25 Navidea Biopharmaceuticals Inc. shares in Q3 2018.
  • SignatureFD first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2016 and held it in 2 quarters.
  • SignatureFD's Navidea Biopharmaceuticals Inc. position peaked at $0 in Q2 2018.
  • 53 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2018.

Based on SignatureFD's 13F filing for Q3 2018, filed 15 Nov 2018.